Moving forward-the 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors and beyond: implications and suggestions for laboratories.

{"article_title":"Moving forward-the 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors and beyond: implications and suggestions for laboratories.","author":"Nayar R, Chhieng DC, Crothers B, Darragh TM, Davey DD, Eisenhut C, Goulart R, Huang EC, Tabbara SO","journal_title":"Journal of the American Society of Cytopathology","issn":"2213-2945","isbn":"","publication_date":"2020-07-01","volume":"9","issue":"4","first_page":"291","page_count":"","accession_number":"32565297","doi":"10.1016\/j.jasc.2020.05.002","publisher":"Elsevier","doctype":"Journal Article","subjects":"Consensus; Early Detection of Cancer methods; Mass Screening methods; Papillomaviridae genetics; Papillomavirus Infections diagnosis; Squamous Intraepithelial Lesions diagnosis; Uterine Cervical Neoplasms prevention & control; Uterine Cervical Dysplasia prevention & control; Adult; Aged; Algorithms; Colposcopy methods; Female; Genotype; Humans; Laboratories, Hospital; Middle Aged; Papillomavirus Infections pathology; Papillomavirus Infections virology; Pathologists; Risk; Squamous Intraepithelial Lesions pathology; Uterine Cervical Neoplasms diagnosis; Uterine Cervical Neoplasms pathology; Young Adult; Uterine Cervical Dysplasia diagnosis; Uterine Cervical Dysplasia pathology","interest_area":["Obstetrics & Gynecology"," Oncology"],"abstract":"The 2019 ASCCP Risk Based Management Consensus Guidelines for prevention of cervical cancer promote clinical management recommendations aligned with our increased understanding of HPV biology and cervical carcinogenesis. They employ HPV-based testing as the basis for risk estimation, allow for personalized risk-based management by incorporating knowledge of current results with prior results, and streamline incorporation of new test methods as they are validated. They continue to support the principles of \"equal management for equal risk\" and \"balancing harms and benefits\" adopted in the 2012 version of the guidelines. These updated guidelines will be able to adjust for decreasing CIN3+ risks as more patients who received HPV vaccination reach screening age. Pathology organizations were closely involved in the development of these guidelines. Herein the pathologists who served as representatives to the 2019 ASCCP guidelines steering committee and workgroups, summarize the changes that are relevant to laboratories, pathologists, and cytotechnologists. Prior relevant screening and reporting recommendations that have not been widely and\/or inconsistently adopted by laboratories are also discussed and considerations for modification of laboratory practices offered. Copyright \u00a9 2020 American Society of Cytopathology. Published by Elsevier Inc. All rights reserved.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=32565297","isPdfLink":false,"isSAML":false,"an":"32565297","number_other":"","type_pub":"","issn_print":"2213-2945","languages":"English","language":"eng","date_entry":"Date Created: 20200623 Date Completed: 20210707 Latest Revision: 20221207","date_update":"20240105","titleSource":"Journal of the American Society of Cytopathology [J Am Soc Cytopathol] 2020 Jul - Aug; Vol. 9 (4), pp. 291-303. Date of Electronic Publication: 2020 May 23.","date_pub_cy":"","type_document":"","contract_publisher":"","authored_on":"2020-07-01","description":"The 2019 ASCCP Risk Based Management Consensus Guidelines for prevention of cervical cancer promote clinical management recommendations aligned with our increased understanding of HPV biology and cervical carcinogenesis. They employ HPV-based testing as the basis for risk estimation, allow for personalized risk-based management by incorporating knowledge of current results with prior results, and streamline incorporation of new test methods as they are validated. They continue to support the principles of "equal management for equal risk" and "balancing harms and benefits" adopted in the 2012 version of the guidelines. These updated guidelines will be able to adjust for decreasing CIN3+ risks as more patients who received HPV vaccination reach screening age. Pathology organizations were closely involved in the development of these guidelines. Herein the pathologists who served as representatives to the 2019 ASCCP guidelines steering committee and workgroups, summarize the changes that are relevant to laboratories, pathologists, and cytotechnologists. Prior relevant screening and reporting recommendations that have not been widely and\/or inconsistently adopted by laboratories are also discussed and considerations for modification of laboratory practices offered.<br \/> (Copyright © 2020 American Society of Cytopathology. Published by Elsevier Inc. All rights reserved.)","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&scope=site&db=mdl&AN=32565297&authtype=shib&custid=ns346513&group=main&profile=eds","no_of_pages":"","authored_by":"Nayar R, Chhieng DC, Crothers B, Darragh TM, Davey DD, Eisenhut C, Goulart R, Huang EC, Tabbara SO"}